New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 14, 2012
10:00 EDTADBE, TER, ESV, CVS, WBMD, SNY, SPW, R, RDS.A, RJF, MRO, ITG, GFIG, HST, EVR, DVA, OFC, BSXOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Adobe (ADBE) upgraded to Outperform from Underperform at JMP Securities... Corporate Office Properties (OFC) upgraded to Neutral from Sell at Citigroup... DaVita (DVA) upgraded to Buy from Neutral at Nomura... Evercore Partners (EVR) upgraded to Outperform from Market Perform at Keefe Bruyette... GFI Group (GFIG) upgraded to Outperform from Market Perform at Keefe Bruyette... Host Hotels (HST) upgraded to Buy from Neutral at Citigroup... ITG (ITG) upgraded to Outperform from Market Perform at Keefe Bruyette... Marathon Oil (MRO) upgraded to Buy from Neutral at Goldman... Raymond James (RJF) upgraded to Outperform from Market Perform at Keefe Bruyette... Royal Dutch Shell (RDS.A) upgraded to Outperform from Neutral at Credit Suisse... Ryder (R) upgraded to Top Pick from Outperform at RBC Capital... SPX Corp. (SPW) upgraded to Buy from Neutral at Nomura... Sanofi (SNY) upgraded to Buy from Hold at Jefferies... WebMD (WBMD) upgraded to Market Perform from Underperform at Raymond James... CVS Caremark (CVS) upgraded to Outperform from Neutral at Macquarie... Ensco (ESV) upgraded to Buy from Hold at Jefferies... Teradyne (TER) upgraded to Outperform from Sector Perform at Pacific Crest... Boston Scientific (BSX) upgraded to Overweight from Underweight at Barclays.
News For A;R;SPW;SNY;WBMD;CVS;ESV;TER;BSX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
October 22, 2014
07:57 EDTRRyder sees Q4 EPS $1.56-$1.61, consensus $1.59
Subscribe for More Information
07:57 EDTRRyder narrows FY14 comparable EPS view to $5.55-$5.60 from $5.50-$5.60
Subscribe for More Information
07:56 EDTRRyder reports Q3 comparable continuing ops EPS $1.63, consensus $1.63
Subscribe for More Information
07:35 EDTSNYCardiometabolic Health Congress to hold annual meeting
Subscribe for More Information
07:07 EDTBSXBoston Scientific raises FY14 adjusted EPS to 81c-83c from 79c-83c
Subscribe for More Information
07:06 EDTBSXBoston Scientific sees Q4 adjusted EPS 20c-22c, consensus 21c
Subscribe for More Information
07:05 EDTBSXBoston Scientific reports Q3 adjusted EPS 20c, consensus 20c
Subscribe for More Information
October 21, 2014
15:35 EDTR, BSXNotable companies reporting before tomorrow's open
Subscribe for More Information
09:03 EDTBSXBoston Scientific receives FDA and CE Mark approvals for CoverEdge leads
Subscribe for More Information
08:03 EDTCVSCVS offering drug plan with higher co-pay at stores selling tobacco, WSJ says
CVS Health (CVS), which stopped selling tobacco products last month, is now offering a prescription-drug plan via its pharmacy benefits unit Caremark that charges patients copayments that are up to $15 higher on prescriptions filled where tobacco is sold, which includes at rival pharmacies operated by Walgreen (WAG) and Rite-Aid (RAD), reported The Wall Street Journal. Reference Link
07:06 EDTSNYFierce Biotech to hold a breakfast meeting
Subscribe for More Information
06:44 EDTSNYActavis among bidders for Omega Pharma, Bloomberg reports
Subscribe for More Information
October 20, 2014
10:37 EDTSNYSanofi unit announces Aubagio gains FDA approval due to study data
Genzyme, a Sanofi company, announced that the Food and Drug Administration has approved the inclusion of efficacy and safety data from the TOWER and TOPIC studies of once-daily, oral Aubagio in the productís U.S. label. In the TOWER study, patients with relapsing MS receiving Aubagio 14 mg had a statistically significant reduction in annualized relapse rate and relative risk of sustained disability progression compared to placebo. In addition, a significant reduction in annualized relapse rate was observed in patients treated with Aubagio 7 mg compared to placebo. The TOPIC study was designed to assess whether initiation of Aubagio in patients who experienced their first neurological symptoms suggestive of MS could prevent or delay a second clinical attack. In this study, the proportion of patients free of relapse was statistically significantly greater for Aubagio 14 mg and 7 mg, compared to placebo. Results of the TOPIC study were published in The Lancet Neurology in September.
08:16 EDTBSXBoston Scientific initiates PLATINUM Diversity trial
Subscribe for More Information
08:06 EDTSNYMerck, Sanofi unit announce pediatric hexavalent vaccine BLA
Subscribe for More Information
07:20 EDTBSXInternational Continence Society to hold annual meeting
ICS Annual Meeting 2014 is being held in Rio de Janeiro, Brazil on October 20-24.
07:19 EDTSNYIBC Life Sciences to hold a conference
Subscribe for More Information
07:11 EDTBSXAmerican Society for Reproductive Medicine to hold annual meeting
2014 Annual Meeting of ASRM is being held in Honolulu on October 18-22.
07:10 EDTA, SNYAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
07:02 EDTSNYRegeneron Sanofi begins dosing in Phase 3 study of dupilumab
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the first patients have been dosed in a Phase 3 clinical study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, in adults with moderate-to-severe atopic dermatitis, or AD, that is not adequately controlled with topical AD medications. LIBERTY AD CHRONOS, the first trial in the Phase 3 clinical program for dupilumab, is a randomized, double-blind, placebo-controlled, multi-national study with the primary objective of demonstrating the efficacy of dupilumab in adults with moderate to severe AD when administered concomitantly with topical corticosteroids through 16 weeks.
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use